AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN)

AVAN 10.04

0.0%

Jun 12 9:41 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (488)	11/11/2003 7:29:58 PM
From: SemiBull	Read Replies (1) of 513

9:16AM Avant Immun's TP10 Inhibitor significantly decreases heart attacks (AVAN) 2.38: Co announces that its TP10 complement Inhibitor significantly decreases heart attacks and death in men following cardiac surgery. Results of a Phase II trial of AVANT's soluble complement inhibitor, TP10 (sCR1), were presented today a at the Annual Scientific Meeting of the American Heart Association. finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next